CBD (Cannabidiol)
Non-intoxicating phytocannabinoid from Cannabis sativa. Modulates endocannabinoid system indirectly (does not bind CB1/CB2 strongly), plus 5-HT1A partial agonism, TRPV1 activation, and GPR55 antagonism. FDA-approved as Epidiolex (100 mg/mL solution) for Dravet/Lennox-Gastaut epilepsy at 5-20 mg/kg/day. Widely used OTC for anxiety, pain, and sleep. Highly lipophilic with low oral bioavailability (6-19%); increases 4-5x with fatty food. CYP3A4/2C19 substrate and inhibitor.
Projected serum levels — 25 mg, as needed (shown daily)
Maintenance schedule: 25 mg as needed (shown daily) (oral).
Loading schedule: 75 mg on day 1, then 25 mg as needed (shown daily) — reaching therapeutic levels sooner.
Modeled steady state after ~8 days: peak ≈ 13.2 mg, trough ≈ 11.0 mg body load. Population-based estimate over 19 days for a 25 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Cannabinoid
- Route modeled
- Oral
- Model confidence
- predicted
- Half-life
- 2.3 days
- Common dose
- 25 mg
- Suggested maximum
- 1.5k mg/day
- Reference dose range
- 5–1.5k mg (single dose)
- Suggested cadence
- as needed (shown daily)
- Validated against
- 750 mg oral — Cmax 0.34 mg/L at 4 h
Documented interactions
-
danger
25I-NBOMe + CBD (Cannabidiol)
25I-NBOMe and CBD (Cannabidiol) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
2C-I (2,5-Dimethoxy-4-iodophenethylamine) + CBD (Cannabidiol)
2C-I (2,5-Dimethoxy-4-iodophenethylamine) and CBD (Cannabidiol) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + CBD (Cannabidiol)
2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and CBD (Cannabidiol) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
4-AcO-DMT (Psilacetin) + CBD (Cannabidiol)
4-AcO-DMT (Psilacetin) and CBD (Cannabidiol) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
-
danger
4-MMC (Mephedrone) + CBD (Cannabidiol)
CBD (Cannabidiol) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x
-
danger
5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) + CBD (Cannabidiol)
5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) and CBD (Cannabidiol) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).
Serum checks 577 modeled interaction pairings for cbd (cannabidiol) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Cannabidiol in anxiety and sleep: a large case series
Prospective case series (72 adults) finding CBD 25-75 mg/day reduced anxiety scores in 79% and improved sleep scores in 67% within the first month, with sustained benefit and good tolerability.
-
Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome (GWPCARE4 trial)
Pivotal RCT establishing Epidiolex (CBD) 10-20 mg/kg/day as effective for Lennox-Gastaut syndrome, reducing drop seizures by 42% versus 17% with placebo, leading to first FDA-approved cannabis-derived drug.
-
Human pharmacokinetics of cannabidiol: a comprehensive review
Comprehensive PK review establishing CBD half-life of 18-32 hours, oral bioavailability of 6-19% (highly food-dependent), tmax 1-6 hours, CYP3A4/2C19 metabolism, and high lipophilicity driving large volume of…
3 published studies referenced in the app, each with a plain-language summary.